Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture
Sponsor
An efficient cell selection method is crucial to delivering a consistent autologous therapy product when the starting material received from severely ill patients is highly variable. While a variety of technologies are being adopted in the industry, there are very few GMP options, and many lack the flexibility for multiple passes, and flexibility in reagent selection. In addition, the currently available technologies are often applied in combination with manufacturing platforms that are manual, semi-automated and lacking commercial viability.
During this webinar, our experts will share insights on obtaining highly purified cells using magnetically active cell selection in a flexible, closed manufacturing system. In addition, we will learn about transitioning manual cell therapy production to automated processes that are scalable to meet clinical and commercial demands.
- Background, and the current status, of the Malaghan Institute’s CD19 cell therapy in a Phase I clinical trial
- Translation of Malaghan's open, manual manufacturing process into a fully automated workflow from sample loading, cell selection to harvest
- Magnetic selection in the Cocoon® Platform and results
You might also like
New methods to separate empty, partial, full and heavy AAV capsids
De-risking cell therapy product development: strategies for commercial success
Establishing the first southern Chinese haplobank of clinical-grade hiPSCs
Meeting the needs for large scale expansion and processing of clinically relevant numbers of functional human NK cells
